[Research Progress of Chimeric Antigen Receptor T Cell Therapy in Acute Myeloid Leukemia--Review]

Chimeric antigen receptor (CAR) T cell immunotherapy has achieved significant clinical efficacy in lymphatic malignancies, and CAR-T therapy for acute myeloid leukemia (AML) has become a research hotspot in recent years. At present, there is no CAR-T target as specific and effective as CD19 in lymphatic system tumors in AML. However, there are more and more new single target or modified CAR-T therapies for AML.The research on combination targeting (dual target) for AML has improved the long-term control problem of AML that cannot be achieved by single spectrum targeted CAR-T in the past. Both single target and dual target CAR-T can improve efficacy and reduce toxicity. This article reviews the latest research progress of CAR-T cell therapy in AML treatment.